Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

IMS 2023 | Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb

Andrew Cowan • 29 Sep 2023

IMS 2023

Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Lenalidomide Pomalidomide

Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses the results of a real-world analysis evaluating the clinical outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar

Novel targets being explored in multiple myeloma and the value of CELMoDs

Andrew Cowan • 29 Sep 2023

Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs

Andrew Cowan • 29 Sep 2023

Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma

Andrew Cowan • 29 Sep 2023

First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma

Andrew Cowan • 11 Dec 2021

Related Videos

Looking forward to COMy 2024: celebrating 10 years

Mohamad Mohty • 17 Apr 2024

Overcoming barriers to treating older patients with myeloma

Sergio Giralt • 16 Apr 2024

The potentially curative role of CAR-T therapy in myeloma

Sergio Giralt • 16 Apr 2024

Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines

Monika Engelhardt • 16 Apr 2024